Clinical Trials
13 trialsNCT01934335 2021-11-01
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
University of Iowa
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00459121 2019-03-26
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00481845 2017-02-07
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Stanford University
Phase 2 Terminated
NCT00686036 2016-12-21
ZENITH
Sanofi
Phase 2 Terminated
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT00290537 2016-05-19
Phase II Study of ZD6474 in Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00402896 2016-03-09
Malignant Pleural Effusion With ZD6474
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00720083 2015-11-17
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT01372813 2015-10-23
Vandetanib to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00683787 2015-01-08
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00445549 2012-06-26
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated